[ad_1]
The UK government is reported to approve the use of the COVID-19 vaccine jointly developed by local pharmaceutical company AstraZeneca and the University of Oxford, later this month. If the approval process goes smoothly, the AstraZeneca vaccine is expected to be vaccinated across the UK, following Pfizer. However, there is much criticism that the clinical trial data presented by the University of Oxford is flawed, so the possibility of delaying approval until next year cannot be ruled out.
The UK Medicines and Healthcare Products Regulatory Authority (MHRA) is expected to approve the use of the AstraZeneca vaccine between 28-29 (local time), according to the Daily Telegraph. It reported on the 18th, citing a high-level government source. Approval is expected to be issued in approximately one week when the final results of the AstraZeneca vaccine clinical trial are presented by the University of Oxford on the 21st. If the AstraZeneca vaccine is approved for use, the UK government will start the first week January next year. Large-scale vaccinations are planned on football fields, racetracks and exhibition halls.
The UK government has become the first in the world to approve the use of Pfizer’s vaccine as a vaccine for COVID-19 and has started vaccinating around the world. If the AstraZeneca vaccine is also approved for the first time in the UK, it is anticipated that other countries, such as the United States, will follow. The Daily Telegraph said: “The AstraZeneca vaccine is much easier to store and inoculate than the Pfizer vaccine, which requires a cryogenic environment,” said the Daily Telegraph. “British health officials hope this vaccine will become a ‘game changer’.”
MHRA stated that it has not been determined whether it will approve the AstraZeneca vaccine. An MHRA spokesperson said in the Daily Telegraph report that “the Oxford-AstraZeneca Corona 19 vaccine review process is currently in progress.” “The MHRA approval process is designed to ensure that the COVID-19 vaccine has reached a high level of safety, quality and prevention,” he said. “Vaccines that do not comply with this will never be approved for use.” .
The skepticism about the AstraZeneca vaccine is also overwhelming. The AstraZeneca vaccine had a low 62% prevention rate when the dose was dosed in two doses at a monthly interval. However, when half the dose was administered in the first vaccination, the prevention rate shot up to 90%. It is speculated that the approval process is delayed due to such erratic data. The Guardian released a statement from a British government source that early approval of the AstraZeneca vaccine is not a confirmed problem and may be postponed after January next year.
Reporter Jo Seong-eun [email protected]
[ad_2]
